Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases (GlobeNewswire) - Mar 22, 2022 - "Plus Therapeutics...announced that the first patient has been dosed in the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM)....The ReSPECT-LM trial (NCT05034497) is a multicenter, sequential cohort, open-label, single dose, dose escalation Phase 1/2a study using a modified Fibonacci 3+3 study design....The primary endpoints of the study are the incidence and severity of adverse events/serious adverse events and dose limiting toxicities."
Trial status • Brain Cancer • CNS Tumor • Oncology
|